Header Logo

Connection

JONATHAN M KURIE to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications JONATHAN M KURIE has written about Lung Neoplasms.
JONATHAN M KURIE
Connection Strength
5.076
Lung Neoplasms
  1. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A. 2023 07 11; 120(28):e2220276120.
    View in: PubMed
    Score: 0.188
  2. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. J Clin Invest. 2023 04 03; 133(7).
    View in: PubMed
    Score: 0.185
  3. Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. JCI Insight. 2022 01 11; 7(1).
    View in: PubMed
    Score: 0.170
  4. The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nat Commun. 2021 11 03; 12(1):6354.
    View in: PubMed
    Score: 0.167
  5. Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity. Cell Rep. 2021 04 20; 35(3):109009.
    View in: PubMed
    Score: 0.161
  6. A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. Commun Biol. 2021 04 19; 4(1):482.
    View in: PubMed
    Score: 0.161
  7. A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. J Clin Invest. 2021 01 04; 131(1).
    View in: PubMed
    Score: 0.158
  8. The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest. 2018 04 02; 128(4):1267-1282.
    View in: PubMed
    Score: 0.130
  9. Thy-1+ Cancer-associated Fibroblasts Adversely Impact Lung Cancer Prognosis. Sci Rep. 2017 07 25; 7(1):6478.
    View in: PubMed
    Score: 0.124
  10. Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11. J Clin Invest. 2017 01 03; 127(1):117-131.
    View in: PubMed
    Score: 0.119
  11. Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. Mol Cancer Res. 2016 Mar; 14(3):287-95.
    View in: PubMed
    Score: 0.111
  12. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J Clin Invest. 2015 Mar 02; 125(3):1147-62.
    View in: PubMed
    Score: 0.105
  13. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest. 2014 Jun; 124(6):2696-708.
    View in: PubMed
    Score: 0.099
  14. Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 2014 Jan; 12(1):3-13.
    View in: PubMed
    Score: 0.097
  15. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One. 2013; 8(6):e67054.
    View in: PubMed
    Score: 0.094
  16. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012 Sep; 122(9):3170-83.
    View in: PubMed
    Score: 0.088
  17. Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression. Mol Cell Biol. 2011 Nov; 31(21):4270-85.
    View in: PubMed
    Score: 0.083
  18. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest. 2011 Apr; 121(4):1373-85.
    View in: PubMed
    Score: 0.080
  19. miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res. 2011 Jan; 9(1):25-35.
    View in: PubMed
    Score: 0.078
  20. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One. 2009; 4(4):e5401.
    View in: PubMed
    Score: 0.070
  21. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 2008 Sep 01; 68(17):7237-45.
    View in: PubMed
    Score: 0.067
  22. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One. 2008 May 21; 3(5):e2220.
    View in: PubMed
    Score: 0.066
  23. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther. 2008 Apr; 7(4):952-60.
    View in: PubMed
    Score: 0.065
  24. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila). 2008 Aug; 1(3):201-7.
    View in: PubMed
    Score: 0.065
  25. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res. 2008 Feb 15; 68(4):1119-27.
    View in: PubMed
    Score: 0.065
  26. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One. 2007 Nov 21; 2(11):e1226.
    View in: PubMed
    Score: 0.064
  27. Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell. 2007 Jul; 12(1):6-8.
    View in: PubMed
    Score: 0.062
  28. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes Dev. 2007 Feb 15; 21(4):361-6.
    View in: PubMed
    Score: 0.060
  29. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol. 2007 Jan; 170(1):366-76.
    View in: PubMed
    Score: 0.060
  30. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006 Apr 15; 66(8):4198-207.
    View in: PubMed
    Score: 0.057
  31. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005 Dec 15; 65(24):11478-85.
    View in: PubMed
    Score: 0.056
  32. Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol. 2005 May; 40(5):263-9.
    View in: PubMed
    Score: 0.053
  33. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 2005 Apr 15; 65(8):3226-35.
    View in: PubMed
    Score: 0.053
  34. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol. 2005 Feb; 25(3):1054-69.
    View in: PubMed
    Score: 0.052
  35. Role of protein kinase B-dependent signaling in lung tumorigenesis. Chest. 2004 May; 125(5 Suppl):141S-4S.
    View in: PubMed
    Score: 0.050
  36. Deguelin-induced inhibition of cyclooxygenase-2 expression in human bronchial epithelial cells. Clin Cancer Res. 2004 Feb 01; 10(3):1074-9.
    View in: PubMed
    Score: 0.049
  37. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):660-4.
    View in: PubMed
    Score: 0.047
  38. Cyclin D1 expression in the field of exposure: another piece in the molecular Auerbach puzzle. J Clin Oncol. 2003 Jun 01; 21(11):2056-8.
    View in: PubMed
    Score: 0.047
  39. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem. 2003 Jun 27; 278(26):23630-8.
    View in: PubMed
    Score: 0.046
  40. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3? protein and represses lung cancer metastasis. Cancer Biol Ther. 2022 12 31; 23(1):265-280.
    View in: PubMed
    Score: 0.045
  41. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res. 2002 Sep; 8(9):2970-5.
    View in: PubMed
    Score: 0.044
  42. Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. 2002 Jul 15; 62(14):3945-9.
    View in: PubMed
    Score: 0.044
  43. Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival. Cancer Res Commun. 2022 07; 2(7):590-601.
    View in: PubMed
    Score: 0.044
  44. A Method for Orthotopic Transplantation of Lung Cancer in Mice. Methods Mol Biol. 2022; 2374:231-242.
    View in: PubMed
    Score: 0.042
  45. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
    View in: PubMed
    Score: 0.042
  46. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.040
  47. The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth. Mol Cancer Res. 2021 04; 19(4):667-677.
    View in: PubMed
    Score: 0.039
  48. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat Commun. 2020 09 09; 11(1):4520.
    View in: PubMed
    Score: 0.039
  49. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene. 2000 Sep 07; 19(38):4432-6.
    View in: PubMed
    Score: 0.039
  50. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.038
  51. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
    View in: PubMed
    Score: 0.037
  52. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Mol Cancer Ther. 2019 10; 18(10):1775-1786.
    View in: PubMed
    Score: 0.036
  53. MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas. Exp Mol Med. 2019 01 17; 51(1):1-10.
    View in: PubMed
    Score: 0.034
  54. Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. J Natl Cancer Inst. 1998 Jul 01; 90(13):991-5.
    View in: PubMed
    Score: 0.033
  55. Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells. Oncogene. 1998 Jun 11; 16(23):3039-46.
    View in: PubMed
    Score: 0.033
  56. Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun. 2018 02 06; 9(1):512.
    View in: PubMed
    Score: 0.032
  57. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells. Cell Growth Differ. 1997 Mar; 8(3):283-91.
    View in: PubMed
    Score: 0.030
  58. Multiplatform-based molecular subtypes of non-small-cell lung cancer. Oncogene. 2017 03; 36(10):1384-1393.
    View in: PubMed
    Score: 0.030
  59. Musashi-2 (MSI2) supports TGF-? signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl Acad Sci U S A. 2016 06 21; 113(25):6955-60.
    View in: PubMed
    Score: 0.029
  60. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Cancer Res. 1995 Dec 01; 55(23):5603-10.
    View in: PubMed
    Score: 0.028
  61. BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells. Mol Cancer. 2015 Sep 22; 14:173.
    View in: PubMed
    Score: 0.027
  62. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
    View in: PubMed
    Score: 0.026
  63. Circulating tumor cells from a 4-dimensional lung cancer model are resistant to cisplatin. J Thorac Cardiovasc Surg. 2014 Sep; 148(3):1056-63; discussion 1063-4.
    View in: PubMed
    Score: 0.025
  64. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int J Cancer. 2014 Feb 15; 134(4):765-77.
    View in: PubMed
    Score: 0.024
  65. Gene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patients. Int J Cancer. 2014 Feb 15; 134(4):789-98.
    View in: PubMed
    Score: 0.024
  66. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. Mol Cancer Ther. 2013 Aug; 12(8):1545-55.
    View in: PubMed
    Score: 0.023
  67. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res. 2013 Jan 15; 73(2):571-82.
    View in: PubMed
    Score: 0.023
  68. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res. 2012 Nov 15; 72(22):6013-23.
    View in: PubMed
    Score: 0.022
  69. Human lung cancer cells grown on acellular rat lung matrix create perfusable tumor nodules. Ann Thorac Surg. 2012 Apr; 93(4):1075-81.
    View in: PubMed
    Score: 0.021
  70. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene. 2010 May 06; 29(18):2616-27.
    View in: PubMed
    Score: 0.019
  71. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59.
    View in: PubMed
    Score: 0.019
  72. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009 Sep 15; 23(18):2140-51.
    View in: PubMed
    Score: 0.018
  73. Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. J Biol Chem. 2009 Jun 26; 284(26):17766-74.
    View in: PubMed
    Score: 0.018
  74. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol. 2009 Apr; 40(4):443-53.
    View in: PubMed
    Score: 0.017
  75. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila). 2008 Oct; 1(5):316-28.
    View in: PubMed
    Score: 0.017
  76. A new method for respiratory gating during microcomputed tomography of lung in mice. J Am Assoc Lab Anim Sci. 2008 Jul; 47(4):46-56.
    View in: PubMed
    Score: 0.017
  77. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila). 2008 Jun; 1(1):39-44.
    View in: PubMed
    Score: 0.017
  78. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep; 132(3 Suppl):56S-68S.
    View in: PubMed
    Score: 0.016
  79. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene. 2007 Oct 18; 26(48):6896-904.
    View in: PubMed
    Score: 0.015
  80. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem. 2007 Feb 09; 282(6):3507-19.
    View in: PubMed
    Score: 0.015
  81. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene. 2007 Apr 19; 26(18):2658-66.
    View in: PubMed
    Score: 0.015
  82. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005 Jan 01; 65(1):226-35.
    View in: PubMed
    Score: 0.013
  83. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.012
  84. A big step in the study of small cell lung cancer. Cancer Cell. 2003 Sep; 4(3):163-6.
    View in: PubMed
    Score: 0.012
  85. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
    View in: PubMed
    Score: 0.012
  86. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.012
  87. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.
    View in: PubMed
    Score: 0.012
  88. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst. 2003 Jan 15; 95(2):165-8.
    View in: PubMed
    Score: 0.011
  89. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.011
  90. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer. 2002 Jul 15; 95(2):340-53.
    View in: PubMed
    Score: 0.011
  91. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002 May; 8(5):1178-84.
    View in: PubMed
    Score: 0.011
  92. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 2002 Feb 15; 94(4):1023-31.
    View in: PubMed
    Score: 0.011
  93. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9.
    View in: PubMed
    Score: 0.011
  94. Prostaglandin E synthase: another enzyme in the cyclooxygenase pathway driving epithelial cancer? Clin Cancer Res. 2001 Sep; 7(9):2608-10.
    View in: PubMed
    Score: 0.010
  95. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst. 2001 Aug 15; 93(16):1257-63.
    View in: PubMed
    Score: 0.010
  96. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res. 2000 Aug; 6(8):2973-9.
    View in: PubMed
    Score: 0.010
  97. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 2000 Apr; 7(4):530-6.
    View in: PubMed
    Score: 0.009
  98. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 2000 Feb; 18(3):609-22.
    View in: PubMed
    Score: 0.009
  99. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 1999 Oct 01; 59(19):4798-803.
    View in: PubMed
    Score: 0.009
  100. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells. Cancer Res. 1999 Aug 01; 59(15):3838-44.
    View in: PubMed
    Score: 0.009
  101. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol. 1999 Aug; 17(8):2309-15.
    View in: PubMed
    Score: 0.009
  102. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
    View in: PubMed
    Score: 0.009
  103. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids. Clin Cancer Res. 1999 Feb; 5(2):431-7.
    View in: PubMed
    Score: 0.009
  104. Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10810-E10811.
    View in: PubMed
    Score: 0.008
  105. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol. 1998 Jun; 25(3 Suppl 8):33-7.
    View in: PubMed
    Score: 0.008
  106. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1998 May; 4(5):1345-55.
    View in: PubMed
    Score: 0.008
  107. Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):331-6.
    View in: PubMed
    Score: 0.008
  108. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst. 1997 Jun 18; 89(12):857-62.
    View in: PubMed
    Score: 0.008
  109. Chemoprevention of respiratory tract cancer. Hematol Oncol Clin North Am. 1997 Jun; 11(3):387-408.
    View in: PubMed
    Score: 0.008
  110. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst. 1997 May 07; 89(9):624-9.
    View in: PubMed
    Score: 0.008
  111. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol. 1996 Feb; 14(2):503-13.
    View in: PubMed
    Score: 0.007
  112. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS One. 2015; 10(4):e0122628.
    View in: PubMed
    Score: 0.007
  113. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993 May 15; 53(10 Suppl):2379-85.
    View in: PubMed
    Score: 0.006
  114. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg. 1992 Nov; 104(5):1465-9.
    View in: PubMed
    Score: 0.006
  115. Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res. 2011 Dec 15; 71(24):7670-82.
    View in: PubMed
    Score: 0.005
  116. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila). 2011 Jun; 4(6):818-28.
    View in: PubMed
    Score: 0.005
  117. In vivo respiratory-gated micro-CT imaging in small-animal oncology models. Mol Imaging. 2004 Jan; 3(1):55-62.
    View in: PubMed
    Score: 0.003
  118. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs. 1998-1999; 16(3):237-43.
    View in: PubMed
    Score: 0.002
  119. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl. 1995; 22:1-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.